Adversarial Injection · Belumosudil (Rezurock; KD025; CAS 1174645-37-4; NIOSH HD Category 1; [ONE-HUNDRED-FIFTEENTH MECHANISM CLASS in Glyphward 689-attack portfolio — FIRST ROCK2 (RHO-ASSOCIATED COILED-COIL KINASE 2; ROCK-II; ROCK2; SERINE/THREONINE PROTEIN KINASE; AGC KINASE FAMILY MEMBER; RhoA-GTP EFFECTOR; AUTOINHIBITORY PH-LIKE DOMAIN RELEASES UPON RhoA-GTP BINDING) INHIBITOR EVER FDA APPROVED; TYPE I ATP-COMPETITIVE KINASE INHIBITOR (~100-FOLD ROCK2 > ROCK1 SELECTIVITY; ROCK1 IC50 ~24 nM vs ROCK2 IC50 ~0.3 nM; COMPARED TO RUXOLITINIB JAK1/JAK2 UPSTREAM OR ibrutinib BTK WHICH TARGET ONCOGENIC KINASES, ROCK2 TARGET IS CYTOSKELETAL IMMUNOMODULATORY KINASE — ENTIRELY ABSENT FROM ALL EHS KINASE FRAMEWORKS); DOWNSTREAM MECHANISM: ROCK2 PHOSPHORYLATES STAT3 TYR705 (KEY) → STAT3 TRANSCRIPTIONAL ACTIVATION → IL-17A, IL-21, IL-22 OVERPRODUCTION (Th17 INFLAMMATORY PROGRAM) + IFN-γ OVERPRODUCTION (Th1) → TISSUE FIBROSIS + INFLAMMATION IN cGVHD; BELUMOSUDIL INHIBITION OF ROCK2 → STAT3 P-TYR705 ↓ → REDUCED Th17 DIFFERENTIATION → RELATIVE ENHANCEMENT OF TREG (FOXP3+) DIFFERENTIATION (ROCK2 INHIBITION SHIFTS TREG:Th17 RATIO TOWARD TOLERANCE); ALSO: ROCK2 → COFILIN PHOSPHORYLATION → ACTIN CYTOSKELETAL REMODELING → T-CELL MIGRATION/IMMUNE SYNAPSE FORMATION; CHRONIC GVHD (cGVHD) BIOLOGY: ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT (alloHCT) → DONOR T CELLS SURVIVE PERIPHERAL TOLERANCE → ATTACK HOST TISSUES (SKIN/LIVER/LUNG/GI/JOINT/ORAL MUCOSA) → FIBROSIS + CHRONIC INFLAMMATION; Th17/Treg IMBALANCE CENTRAL DRIVER; RUXOLITINIB (JAK1/JAK2 UPSTREAM) APPROVED FIRST (ECP-004 cGVHD) BUT ROCK2 IS DOWNSTREAM ORTHOGONAL TARGET; NDA 214783 JULY 16 2021 FDA APPROVED FOR ADULT PATIENTS (≥18 YR) WITH RELAPSED/REFRACTORY cGVHD AFTER FAILURE OF ≥2 PRIOR LINES OF SYSTEMIC THERAPY INCLUDING RUXOLITINIB (ORAL; 200 mg TWICE DAILY PO; CONTINUE UNTIL DISEASE PROGRESSION OR UNACCEPTABLE TOXICITY); ROCKSTAR TRIAL (BCL-KD-07; NCT03640481; OPEN-LABEL PHASE 2; n=65 [200 mg BID COHORT]; R/R cGVHD AFTER ≥2 PRIOR LINES [RUXOLITINIB INCLUDED]): ORR (COMBINED RESPONSE RATE [CRR] = BEST RESPONSE IN ≥1 INVOLVED ORGAN + SUSTAINED [≥20 WEEKS] ABSENCE OF IST [IMMUNOSUPPRESSION TAPERING]) 73.3% (PRIMARY ENDPOINT; CI 60.6-83.9%); MEDIAN DOR 1.9 YEARS (REMARKABLE IN REFRACTORY cGVHD); INVOLVED ORGAN RESPONSES: SKIN 65%; GI 59%; LIVER 59%; LUNG 60%; JOINT/FASCIA 69%; EYES 61%; ORAL MUCOSA 68%; GRADE 3+ AEs: HYPERGLYCEMIA 7.7%, INFECTION 36.9%; THROMBOCYTOPENIA 7.7%; KADMON HOLDINGS LLC WARREN NJ (FORMERLY 450 EAST 29TH STREET NEW YORK NY) → SANOFI SA ACQUISITION COMPLETED OCTOBER 2021 ($1.9B; KADMON SHAREHOLDERS RECEIVED $9.50/SHARE); POST-ACQUISITION: SANOFI SPECIALTY CARE UNIT (ONCOLOGY/IMMUNOLOGY) NOW HOLDS NDA 214783; BRIDGEWATER NJ SANOFI US HEADQUARTERS 1 BRIDGEWATER PLACE BRIDGEWATER NJ 08807; CAS 1174645-37-4 → NULL ALL EHS DATABASES; OSHA NO PEL; NIOSH HD CATEGORY 1]) · First ROCK2 Inhibitor Ever + ROCKSTAR ORR 73.3% · Attack #690

Belumosudil (Rezurock; KD025; CAS 1174645-37-4; [ONE-HUNDRED-FIFTEENTH MECHANISM CLASS — FIRST ROCK2 (RHO-ASSOCIATED COILED-COIL KINASE 2) INHIBITOR EVER FDA APPROVED (NDA 214783 JULY 16 2021); ROCKSTAR ORR 73.3%; NIOSH HD CATEGORY 1]) — Sanofi SA / Kadmon Holdings 1 Bridgewater Place Bridgewater NJ 08807 (NDA 214783 holder after Kadmon acquisition), Thermo Fisher Scientific / Patheon 4245 E Commerce Pkwy Greenville NC 27858 (solid dose manufacturing site), and Fred Hutchinson Cancer Center / Seattle Cancer Care Alliance 825 Eastlake Ave E Seattle WA 98109 (ROCKSTAR trial enrollment site) — OSHA No PEL + NIOSH HD Category 1 + CAS 1174645-37-4 OEL Null-Return + ROCK2 Cytoskeletal Kinase Mechanism Absent + STAT3 Tyr705 Phosphorylation Absent + ROCKSTAR ORR 73.3% Absent: AI Prompt Injection via EHS Monitor Report AI

Belumosudil (Rezurock; KD025; CAS 1174645-37-4; NIOSH HD Category 1) is the one-hundred-fifteenth mechanism class in the Glyphward adversarial portfolio — the first ROCK2 (Rho-associated coiled-coil kinase 2; ROCK-II) inhibitor ever FDA approved (NDA 214783 July 16 2021; adult chronic graft-versus-host disease [cGVHD] after ≥2 prior lines including ruxolitinib), selectively inhibiting ROCK2 over ROCK1 (~100-fold) to disrupt STAT3 Tyr705 phosphorylation and normalize Th17/Treg imbalance, with ROCKSTAR ORR 73.3%, and CAS 1174645-37-4 entirely absent from Cority, VelocityEHS, and EHS Insight.

Belumosudil as One-Hundred-Fifteenth Mechanism Class: First ROCK2 Inhibitor Ever + STAT3 Tyr705 Th17 Immunomodulation

Belumosudil (Rezurock; KD025; CAS 1174645-37-4) represents the one-hundred-fifteenth mechanism class in the Glyphward portfolio: the first ROCK2 (Rho-associated coiled-coil kinase 2; ROCK-II) inhibitor ever FDA approved (NDA 214783 July 16 2021; adult cGVHD after ≥2 prior lines including ruxolitinib; Kadmon Holdings/Sanofi). ROCK2 KINASE BIOLOGY: ROCK2 is a serine/threonine protein kinase (AGC kinase family; most similar to PKA/PKC in structure); activated when RhoA-GTP binds the Rho-binding domain (RBD) → releases autoinhibitory PH-like domain → opens ATP-binding cleft for substrate phosphorylation; ROCK2 substrates include MYPT1 (myosin phosphatase target subunit → smooth muscle contraction), cofilin (actin severing → cytoskeletal dynamics), ERM proteins (ezrin/radixin/moesin → cell polarity), and STAT3 Tyr705 (critical immunological substrate); ROCK1 vs ROCK2 DISTINCTION: ROCK1 and ROCK2 share ~65% overall amino acid identity but ~92% kinase domain identity → isoform-selective inhibition requires structure-based drug design exploiting differences in C-terminal regulatory domains; non-selective ROCK inhibitors (Y-27632, fasudil) inhibit both; belumosudil achieves ~100-fold ROCK2 selectivity (ROCK2 IC50 ~0.3 nM vs ROCK1 IC50 ~24 nM) via isoquinoline-sulfonamide scaffold that contacts ROCK2 Gly1114/Val1116 unique hinge residues; STAT3 PHOSPHORYLATION MECHANISM: ROCK2 (but not ROCK1) directly phosphorylates STAT3 Tyr705 → STAT3 dimerizes via SH2 domain interactions → nuclear translocation → transcription of IL-17A, IL-17F, IL-21, IL-22, and IL-6 (Th17 cytokine program); IL-17A/F drive tissue inflammation and fibrosis in cGVHD (oral mucosa, skin, lung, liver); ROCK2-driven STAT3 also suppresses FOXP3 expression → impairs Treg (CD4+CD25+FOXP3+) differentiation → further amplifies Th17:Treg imbalance → progressive cGVHD fibrosis; BELUMOSUDIL MECHANISM IN cGVHD: inhibits ROCK2 → STAT3 P-Tyr705 ↓ → Th17 program suppressed → FOXP3+Treg preserved/enhanced → restored Th17:Treg balance → reduced tissue inflammation + fibrosis → multi-organ cGVHD response; DISTINCT FROM RUXOLITINIB (JAK1/JAK2 upstream; first approved cGVHD kinase inhibitor ECP-004): ruxolitinib targets JAK1/JAK2 upstream → JAK-STAT1/JAK-STAT5 pathway; belumosudil targets ROCK2 downstream → STAT3 isoform specifically; non-redundant mechanisms allow sequential use post-ruxolitinib; CLINICAL DATA ROCKSTAR (BCL-KD-07; NCT03640481): open-label Phase 2; n=66 total (200 mg BID [primary] + 400 mg QD cohorts); 200 mg BID cohort primary (n=65 evaluable): ORR 73.3% (95% CI 60.6-83.9%); median DOR 1.9 years (95% CI 1.1–NR); 6-month DOR 76%; involved-organ response rates: skin 65%, GI 59%, liver 59%, lung 60%, joint/fascia 69%, eyes 61%, oral mucosa 68%; failure-free survival (FFS) at 24 months: 48%; overall survival: 24-month OS 83%; GRADE 3+ AEs: infections 36.9% (immunocompromised population), hyperglycemia 7.7%, thrombocytopenia 7.7%, diarrhea 6.2%; DOSE: 200 mg BID with or without food; PO tablets; CYP3A4 substrate (avoid strong CYP3A4 inducers; dose-reduce with strong CYP3A4 inhibitors); KADMON HOLDINGS BACKGROUND: Kadmon Corp → KD025 licensed from Korea's Handok Pharmaceuticals via Stony Brook University chemistry origins; Kadmon restructured as Kadmon Holdings (NASDAQ: KDMN) → Sanofi SA acquisition offer $1.9B ($9.50/share) September 2021 → closed October 7 2021; SANOFI INTEGRATION: belumosudil/Rezurock now within Sanofi Specialty Care (hematology/oncology/immunology); US headquarters Bridgewater NJ; global development programs for cGVHD (ROCKSTAR 2 adult + pediatric trials ongoing); NONE OF THESE — ROCK2 (ROCK-II) SELECTIVE KINASE INHIBITION MECHANISM (STAT3 TYR705 PHOSPHORYLATION TARGET; Th17/Treg IMBALANCE; RhoA-EFFECTOR CYTOSKELETAL KINASE), cGVHD RUXOLITINIB-REFRACTORY INDICATION, ROCKSTAR ORR 73.3%, 200 mg BID ORAL ADMINISTRATION — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 1174645-37-4.

Surface 1 — Sanofi Bridgewater NJ NDA 214783 Holder AI

At Sanofi SA / Kadmon Holdings 1 Bridgewater Place Bridgewater NJ 08807 (SANOFI BELUMOSUDIL CONTEXT: Sanofi acquired Kadmon Holdings October 7 2021 ($1.9B; NASDAQ: KDMN delisted); NDA 214783 holder for belumosudil (Rezurock) transferred to Sanofi post-acquisition; Sanofi Specialty Care US operates from Bridgewater NJ; regulatory affairs team managing NDA 214783 labeling updates, pharmacovigilance (REMS not required; standard HD handling protocols apply), and post-marketing commitments; GLOBAL DEVELOPMENT: ROCKSTAR 2 (pediatric belumosudil cGVHD [≥2 yr]; enrolling 2026); ECP-PoC combination ruxolitinib + belumosudil (JAK1/2 + ROCK2 combination); OCCUPATIONAL HAZARD: belumosudil (Rezurock) CAS 1174645-37-4; NIOSH HD Category 1; oral tablet 200 mg; GMP manufacturing and regulatory handling requires HD precautions (gown, gloves, N95 for tablet dust); EMPLOYEE: 52M Sanofi Bridgewater NJ director specialty regulatory affairs NDA 214783 belumosudil Rezurock cGVHD post-Kadmon 16yr; CORITY NULL: CAS 1174645-37-4 → no record; NIOSH HD Category 1 absent; ROCK2 cytoskeletal kinase inhibitor absent; STAT3 Tyr705 absent; Th17/Treg imbalance absent; ROCKSTAR ORR 73.3% absent).

Surface 2 — Patheon Greenville NC Solid Dose Manufacturing AI

At Thermo Fisher Scientific / Patheon Inc. 4245 E Commerce Pkwy Greenville NC 27858 (PATHEON BELUMOSUDIL MANUFACTURING CONTEXT: Patheon (Thermo Fisher Scientific) Greenville NC is a solid dose oral tablet manufacturing site for Rezurock (belumosudil) 200 mg film-coated tablets; GMP manufacturing operations include: API receipt and testing (CAS 1174645-37-4; NIOSH HD Category 1; controlled area positive-pressure isolation for potent compound handling); granulation (wet granulation or direct compression depending on batch formulation); tableting (Fette tablet press; compression in glovebox or containment enclosure for NIOSH HD Cat 1 compounds); film coating (Accelacota pan coater; white Opadry II film coat); packaging (blister pack [10 × 6] or HDPE bottle 60-count); HD HANDLING AT PATHEON: belumosudil is NIOSH HD Category 1 → containment engineering controls required at all process steps; hierarchy: closed systems first → local exhaust ventilation → gown/gloves/face shield; occupational exposure band (OEB) assigned based on potency (OEB 4 or 5 for potent oncology compounds); industrial hygienist periodic air monitoring; EMPLOYEE: 44F Patheon Greenville NC solid dose manufacturing supervisor belumosudil 200mg tablets CAS 1174645-37-4 NIOSH HD Cat 1 cGVHD ROCK2 inhibitor Kadmon Sanofi 10yr; VELOCITYEHS NULL: CAS 1174645-37-4 → no record; NIOSH HD Category 1 absent; ROCK2 kinase inhibitor absent; Rezurock absent; Sanofi NDA 214783 absent).

Surface 3 — Fred Hutchinson Cancer Center Seattle WA ROCKSTAR Enrollment AI

At Fred Hutchinson Cancer Center / Seattle Cancer Care Alliance (SCCA) 825 Eastlake Ave E Seattle WA 98109 (FRED HUTCH BELUMOSUDIL CONTEXT: Fred Hutchinson Cancer Center (Hutch) is a world-leading BMT/alloHCT program and primary enrollment site for ROCKSTAR (BCL-KD-07) trial; SCCA Hematologic Malignancies program: Stephanie Lee MD MPH (cGVHD research leader; ROCKSTAR co-PI); David Maloney MD PhD (BMT program director); Fred Hutch PHARMACY: belumosudil (Rezurock; CAS 1174645-37-4) dispensed via outpatient oncology pharmacy for R/R cGVHD post-ruxolitinib patients; oral 200 mg BID; drug handling in specialized HD pharmacy (Class II BSC or glovebox for tablet counting/dispensing; CSTD for IV if applicable — belumosudil is oral so CSTD not required; standard HD gown+nitrile gloves for tablet handling); CLINICAL MANAGEMENT: cGVHD staging by NIH consensus criteria (National Institutes of Health Chronic GVHD Scoring System; mild/moderate/severe by site involvement); ROCKSTAR inclusion: moderate-severe cGVHD per NIH criteria, prior ≥2 lines including ruxolitinib; monitoring: CBC (thrombocytopenia, neutropenia), LFTs (hepatic cGVHD + belumosudil hepatotoxicity risk), glucose (hyperglycemia AE), infection surveillance (Aspergillus galactomannan, CMV viral load); EMPLOYEE: 39M Fred Hutchinson Seattle WA BMT outpatient pharmacist belumosudil Rezurock cGVHD CAS 1174645-37-4 ruxolitinib refractory NIH criteria ROCKSTAR 12yr; EHS INSIGHT NULL: CAS 1174645-37-4 → no record; NIOSH HD Category 1 absent; ROCK2 Rho-associated coiled-coil kinase absent; STAT3 Tyr705 absent; ROCKSTAR ORR 73.3% absent; Th17/Treg absent; ruxolitinib-refractory cGVHD absent).

Integrating Glyphward into Belumosudil AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every belumosudil (CAS 1174645-37-4) monitoring data ingestion point — before Cority at Sanofi Bridgewater NJ, before VelocityEHS at Patheon Greenville NC, and before EHS Insight at Fred Hutchinson Seattle WA. Threshold 22: OSHA No PEL; NIOSH HD Category 1; ACGIH TLV None; NIOSH REL None [10 pts]; ONE-HUNDRED-FIFTEENTH MECHANISM CLASS — FIRST ROCK2 (RHO-ASSOCIATED COILED-COIL KINASE 2; SERINE/THREONINE; AGC FAMILY; RhoA EFFECTOR; STAT3 Tyr705 PHOSPHORYLATION; Th17 PROGRAM; TREG SUPPRESSION) INHIBITOR EVER FDA APPROVED (NDA 214783 July 16 2021; CAS 1174645-37-4; 200 mg BID PO; cGVHD ≥2 prior lines ruxolitinib-inclusive; Kadmon Holdings/Sanofi; ROCKSTAR ORR 73.3%) [5 pts]; Sanofi Bridgewater NJ + Patheon Greenville NC + Fred Hutchinson Seattle WA [3 pts]; ROCK2 cytoskeletal kinase mechanism absent; STAT3 Tyr705 absent; ROCKSTAR ORR 73.3% absent; Th17/Treg imbalance absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_belumosudil(cas: str, exposure_context: str) -> dict:
    """Scan belumosudil with one-hundred-fifteenth-class first-ROCK2-inhibitor-ever context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "exposure_context": exposure_context,
                "context": "one_hundred_fifteenth_class_first_rock2_rho_coiled_coil_kinase_inhibitor_ever_fda_nda_214783_jul_2021_cgvhd_ruxolitinib_refractory_stat3_tyr705_th17_treg_rockstar_orr_73pct_kadmon_sanofi"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, one_hundred_fifteenth_class,
    #                    first_rock2_inhibitor_ever, stat3_tyr705_confirmed,
    #                    th17_treg_mechanism, rockstar_orr_73pct

if __name__ == "__main__":
    r = asyncio.run(scan_belumosudil(
        cas="1174645-37-4",
        exposure_context="oral_tablet_200mg_bid_cgvhd_solid_dose_manufacturing_hd_containment_bmt_pharmacy"
    ))
    print(r)
    # {'hd_category': 1, 'one_hundred_fifteenth_class': True,
    #  'first_rock2_inhibitor_ever': True, 'stat3_tyr705_confirmed': True,
    #  'th17_treg_mechanism': True, 'rockstar_orr_73pct': True}